natgillin/translations-raw huggingface dataset:
Injicér indholdet af sprøjten i hætteglasset med AVONEX ved at sætte den forfyldte sprøjte sammen med BIO-SET anordningen.
Inject the content of the syringe into the vial of AVONEX by connecting the pre-filled syringe to the BIO-SET device.
Injicér insulinet under huden.
Inject the insulin under the skin.
Injicér intraperitonelt langs midtlinien, ½ til 1 finnelængde foran bugfinnen.
Inject intraperitoneally along the central line, 1/2 to 1 fin length in front of the pelvic fin base.
Injicér langsomt (1-2 minutter/injektion) intramuskulært i balden (glutealområdet).
Administer intramuscularly slowly (1-2 minutes/injection) into the buttock (gluteal area).
Injicér langsomt alt vandet fra sprøjten ind i hætteglasset.
Slowly inject all the water from the syringe into the vial.
Injicér langsomt de 6,0 ml 0,9% natriumchlorid-injektionsvæske ned i hætteglasset med det opblandede NovoThirteen.
Slowly inject the 6.0 ml sodium chloride 0.9%, solution for injection, into the reconstituted NovoThirteen vial.
Injicér langsomt over 2-5 minutter.
Inject slowly over 2 to 5 minutes.
Injicér Liprolog Basal under huden, som du er blevet instrueret.
Inject under the skin, as you were taught.
Injicér Liprolog Basal under huden.
Inject Liprolog Basal under the skin.
Injicér Liprolog Mix25 under huden, som du er blevet instrueret.
Inject under the skin, as you were taught.
Injicér Liprolog Mix25 under huden.
Inject Liprolog Mix25 under the skin.
Injicér Liprolog Mix50 under huden, som du er blevet instrueret.
Inject under the skin, as you were taught.
Injicér Liprolog Mix50 under huden.
Inject Liprolog Mix50 under the skin.
Injicér luften i hætteglasset
Inject the air into the vial.
Injicér luften i hætteglasset med hurtigtvirkende insulin.
Inject the air into the fast acting insulin vial.
Injicér luften i hætteglasset med Ultratard, og træk nålen ud
Inject the air into the Ultratard vial, then pull out the needle
Injicér luften i hætteglasset:
Inject the air into the vial.
Injicér luften i hætteglasset: Stik nålen igennem gummiskiven og tryk stemplet i bund
Inject the air into the vial: push the needle through the rubber stopper and press the plunger
Injicér luften i hætteglasset: Stik nålen igennem gummiskiven, og tryk stemplet i bund
Inject the air into the vial: push the needle through the rubber stopper and press the plunger
Injicér luften ind i hætteglasset
Inject the air into the vial.
Injicér luften ind i hætteglasset med den langtidsvirkende insulin, og træk nålen ud
Inject the air into the vial containing long–acting insulin and pull out the needle.
Injicér luften tilbage i hætteglasset, hvis der på noget tidspunkt er for meget luft i sprøjten.
If, at any point, there is too much air in the syringe, inject the air back into the vial.
Injicér lægemidlet ved at presse langsomt og jævnt på stemplet (pres stemplet helt i bund, til injektionssprøjten er tom).
Inject the medicine by using a slow, steady push (push the plunger all the way in until the syringe is empty).
Injicér medicin
Inject medicine
Injicér medicin (figur I)
Inject medicine (Figure I)
Injicér opløsningen som en 3-5 sekunders intravenøs injektion gennem et perifert eller centralt intravenøst kateter ind i en vene.
Inject the solution as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter into a vein.
Injicér opløsningen subkutant i en vinkel på 45-90 °.
Inject the solution subcutaneously, under a 45-90°angle.
Injicér straks.
Inject straight away.
Injicér største læsion(er) først.
Inject largest lesion(s) first.
Injicér suspensionen gennem plastikkanylen, minimum en 20 G med en maksimal injektionstid på 1,0 ml/s.
Inject the suspension through the plastic cannula, no smaller than 20 G at a maximum injection rate of 1.0 ml/s.
Inkl. kliniske frakturer på torakale og lumbale ryghvirvler
Including clinical thoracic and clinical lumbar vertebral fractures
Inkludere forsøgspersoner i alt
Total enrolled subjects
Inkluderede forsøgspersoner i alt
Total enrolled subjects
Inkluderede forsøgspersoner i alt N= 99
Total enrolled subjects N= 99
Inkluderede patienter har ikke responderet på mindst én konventionel behandling, herunder kortikosteroider, immunmodulatorer og/eller TNFα-antagonister (herunder primære non-respondere).
Enrolled patients have failed at least one conventional therapy, including corticosteroids, immunomodulators, and/or TNFα antagonists (including primary non-responders).
Inkluderede patienter havde manglende respons på mindst én konventional behandling, herunder kortikosteroider, immunmodulerende lægemidler og/eller TNFα-antagonisten infliximab (herunder primære non-respondere).
Enrolled patients had failed at least one conventional therapy, including corticosteroids, immunomodulators, and/or the TNFα antagonist infliximab (including primary non-responders).
Inkluderede personer i alt n = 28
Total subjects4 N=28
Inkluderede personer i alt n = 3
Total enrolled subjects
Inkluderede personer i alt n = 5
Total enrolled subjects
Inkluderede personer i alt n = 51
Total subjects4 N=51
Inkluderede personer i alt2 n = 2
Total enrolled subjects2
Inkluderede personer i alt2 n = 2
Total enrolled subjects2 N=2
Inkluderede tumortyperne: Ewing’s sarkom/primitiv neuroektoderm tumor, neuroblastoma, osteoblastoma og rhabdomyosarcoma.
Tumour types included were Ewing's Sarcoma/primitive neuroectodermal tumour, neuroblastoma, osteoblastoma, and rhabdomyosarcoma.
Inkluderer hævelse, som er mest udtalt i hoved og hals, inklusive i ansigtet, læber, tunge, hals eller i meget sjældne tilfælde af andre dele af kroppen (angioødem).
Including swelling most apparent in the head and neck, including the face, lips, tongue, throat or any other part of the body (angioedema) in very rare cases.
Inkluderer kliniske frakturer i vertebrae, hofte, underarm og humerus ifølge WHO's definitioner.
Includes clinical vertebral, hip, forearm, and humerus fractures, as defined by the WHO.
Inkluderer kliniske vertebrale frakturer og non-vertebrale frakturer.
Includes clinical vertebral fractures and non-vertebral fractures.
Inkluderer patienter med recidiv og patienter med delvist eller nul respons inden behandling med interferon (pegyleret eller ikke-pegyleret) med eller uden ribavirin.
Includes relapsers, partial and null reponders to prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin.
Inkluderer patienter med recidiv og patienter med delvist eller nul respons på tidligere behandling med interferon (pegyleret eller ikke-pegyleret) med eller uden ribavirin.
Includes relapsers, partial and null reponders to prior treatment with interferon (pegylated or non-pegylated), with or without ribavirin.
Inkluderer patienter, som havde hiv 1-rna ≥ 50 kopier/ml i uge 24-perioden, patienter, som seponerede tidligt pga. manglende virkning eller tab af virkning, patienter, som seponerede af andre årsager end bivirkninger eller død, og som på seponeringstidspunktet havde en viral belastning ≥ 50 kopier/ml.
Includes patients who had HIV-1 RNA ≥ 50 copies/mL in the week 24 window, patients who discontinued early due to lack or loss of efficacy, patients who discontinued for reasons other than an adverse event or death, and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Inkluderer patienter, som seponerede af andre årsager end bivirkninger, død eller manglende virkning/tab af virkning, f.eks. tilbagetrækning af samtykke, manglende opfølgning osv.
Includes patients who discontinued for reasons other than an adverse event, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.
Inkluderer patienter, som seponerede pga. bivirkninger eller død på et hvilket som helst tidspunkt fra dag 1 til og med uge 24-perioden, hvilket resulterede i ingen virologiske data for behandlingen i løbet af det angivne periode.
Includes patients who discontinued due to adverse event or death at any time point from day 1 through the week 24 window resulting in no virologic data on treatment during the specified window.
Inkluderer pelvis, distale femur, proksimale tibia, ribben, proksimale humerus, underarm og hofte.
Includes pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm, and hip.
Inkluderer tilfælde indberettet inden for de samlede betegnelser: a Synsforstyrrelser (nedsat syn, sløret syn, fotopsi, mouches volantes, nedsat synsskarphed, akkomodationslidelse, presbyopi) b Perikarditis (perikardieeffusion, perikarditis) c Bradykardi (bradykardi, sinusbradykardi) d Pneumonitis (interstitiel lungesygdom, pneumonitis) e Mavesmerter (mavesmerter, øvre mavesmerter, maveubehag, epigastrisk ubehag) f Øsofagussygdom (dyspepsi, gastroøsofageal reflukssygdom, dysphagi) g Unormale resultater af leverfunktionstests (unormal leverfunktion, hyperbilirubinæmi) h Levertoksicitet (lægemiddelinduceret leverskade, kolestatisk hepatitis, hepatocellulær skade, levertoksicitet) i Udslæt (udslæt, acneiform dermatitis, maculopapulært udslæt) j Nyresvigt (akut nyresvigt, nyresvigt) k Nedsat nyrefunktion (azotæmi, nedsat nyrefunktion) l Træthed (træthed, asteni) m Unormale resultater af leverlaboratorietests (forhøjet alaninaminotransferase, forhøjet aspartataminotransferase, forhøjet gamma-glutamyltransferase, forhøjet blodbilirubin, forhøjede transaminaser, forhøjede leverenzymer, unormal leverfunktionstest)
Includes cases reported within the clustered terms: a Vision disorder (vision impairment, vision blurred, photopsia, vitreous floaters, visual acuity reduced, accommodation disorder, presbyopia) b Pericarditis (pericardial effusion, pericarditis) c Bradycardia (bradycardia, sinus bradycardia) d Pneumonitis (interstitial lung disease, pneumonitis) e Abdominal pain (abdominal pain, abdominal pain upper, abdominal discomfort, epigastric discomfort) f Oesophageal disorder (dyspepsia, gastro-oesophageal reflux disease, dysphagia) g Abnormal liver function test (hepatic function abnormal, hyperbilirubinaemia) h Hepatotoxicity (drug-induced liver injury, hepatitis cholestatic, hepatocellular injury, hepatotoxicity) i Rash (rash, dermatitis acneiform, rash maculopapular) j Renal failure (renal failure acute, renal failure) k Renal impairment (azotaemia, renal impairment) l Fatigue (fatigue, asthenia) m Liver laboratory test abnormalities (alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, blood bilirubin increased, transaminases increased, hepatic enzyme increased, liver function test abnormal)
Inkluderer vertebrale og non-vertebrale frakturer
Includes vertebral and non-vertebral fractures
Inkluderet i bilag II for alle føde producerende arter
Included in Annex II for all food producing species
Inkludér en yderligere luftbuffer på 3 ml i 50 ml injektionssprøjten.
An additional air buffer of at least 3 ml is included in the 50 ml syringe.
Inklusion af bevacizumab i et kombinationsregime har ingen indflydelse på initialdosis af capecitabin.
The inclusion of bevacizumab in a combination regimen has no effect on the starting dose of capecitabine.
Inklusionsalderen var fra 13 til 66 år.
Age at inclusion was from 13 to 66 years.
Inklusionskriterier: at overholde kriterier baseret på indikationen i produktresuméet.
Inclusion criteria: to meet criteria based on SmPC indication.
Inklusionskriterierne omfattede en CF-baseline med en forventet FEV1 mellem 25% og 75% og kronisk P. aeruginosa-lungeinfektion.
Entry criteria included CF, baseline FEV1 between 25% and 75% predicted, and chronic
Inklusive dødelige tilfælde
5 Includes fatal cases
Inklusive foretrukne termer for overfølsomhed, lægemiddeloverfølsomhed, anafylaktisk reaktion, anafylaktisk shock, anafylaktoid reaktion, anafylaktoidt shock.
Including preferred terms hypersensitivity, drug hypersensitivity, anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, anaphylactoid shock.
inklusive neutropeni og uveitis er
including neutropenia and
inklusive svær
including severe
inklusive tandudtrækning
including tooth extraction
inklusive udtrækning af
Including tooth extraction.
inkohærens, bevidsthedstab, koma, stupor, krampeanfald, cerebrovaskulær sygdom, encefalopati
incoherence, loss of consciousness, coma, stupor, convulsions, cerebrovascular accident, encephalopathy
Inkompatibilitet:
Incompatibilities:
Inkontinens (manglende evne til at kunne tilbageholde urin)
Urinary incontinence (inability to retain adequate urine)
inkontinens, smerte ved vandladning ufrivillige bevægelser af mund, tunge og lemmer (tardiv dyskinesi).
pain when passing urine. uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia).
Inkrement
68.6
Inkrement al
Incremental recovery
Inkremental recovery (kg/ml)
Incremental recovery (kg/mL)
Inkrementel
16.96
Inkubation af monocyter med Cimzia resulterede i en dosisafhængig hæmning af lipopolysakkarid (LPS)-induceret TNF-α og IL-1β produktion i humane monocytter.
Incubation of monocytes with Cimzia resulted in a dose-dependent inhibition of lipopolysaccharide (LPS)-induced TNFα and IL1β production in human monocytes.
Inkubation med levermikrosomer fra rotter, hunde og mennesker samt humane hepatocytter producerede ikke nogle sporbare regadenoson- metabolitter.
Incubation with rat, dog, and human liver microsomes as well as human hepatocytes produced no detectable metabolites of regadenoson.
Inkubér under disse betingelser i 10 min.
Incubate for 10 minutes in this condition.
Inlyta 1 mg filmovertrukne tabletter
Inlyta 1 mg film-coated tablets
Inlyta 1 mg filmovertrukne tabletter axitinib
Inlyta 1 mg film-coated tablets axitinib
Inlyta 3 mg filmovertrukne tabletter
Inlyta 3 mg film-coated tablets
Inlyta 3 mg filmovertrukne tabletter axitinib
Inlyta 3 mg film-coated tablets axitinib
Inlyta 3 mg fås i beholdere med 60 tabletter og i blisterpakninger med 28 tabletter og 56 tabletter.
Inlyta 3 mg is available in bottles of 60 tablets and blister packs of 28 tablets and 56 tablets.
Inlyta 5 mg filmovertrukne tabletter
Inlyta 5 mg film-coated tablets
Inlyta 5 mg filmovertrukne tabletter axitinib
Inlyta 5 mg film-coated tablets axitinib
Inlyta 5 mg fås i beholdere med 60 tabletter og i blisterpakninger med 28 tabletter og 56 tabletter.
Inlyta 5 mg is available in bottles of 60 tablets and blister packs of 28 tablets and 56 tablets.
Inlyta 7 mg filmovertrukne tabletter axitinib
Inlyta 7 mg film-coated tablets axitinib
Inlyta 7 mg fås i beholdere med 60 tabletter og i blisterpakninger med 28 tabletter og 56 tabletter.
Inlyta 7 mg is available in bottles of 60 tablets and blister packs of 28 tablets and 56 tablets.
Inlyta anvendes, når behandlingen med Sutent (sunitinib) eller "cytokiner" (andre lægemidler mod kræft) har slået fejl.
Inlyta is used when treatment with Sutent (sunitinib) or ‘cytokines’ (other cancer medicines) has failed.
Inlyta kan skade ufødte børn og børn, der bliver ammet.
Inlyta could harm an unborn baby or breast-fed baby.
InnoLet dispenserer 1-50 enheder i spring på 1 enhed.
InnoLet delivers 1-50 units in increments of 1 unit.
InnoLet kan renses udvendigt med en medicinsk serviet.
You can clean your InnoLet by wiping it with a medicinal swab.
InnoLet leverer 1- 50 enheder, stigende med 1 enhed.
InnoLet delivers 1-50 units in increments of 1 unit.
InnoLet leverer 1-50 enheder, stigende med 1 enhed.
InnoLet delivers 1-50 units in increments of 1 unit.
InnoLet må ikke genopfyldes.
Do not refill your InnoLet.
Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY Storbritannien
Innovation House, 70 Norden Road, Maidenhead, Berkshire, SL6 4AY United Kingdom
Innovax-ILT er en veterinær vaccine til beskyttelse af kyllinger mod infektiøs laryngotrakeitis (ILT) og Mareks sygdom (MD).
Innovax-ILT is a veterinary vaccine used to protect chickens against infectious laryngotracheitis (ILT) and Marek’s disease (MD).
Innovax-ILT, suspension og solvens til injektionsvæske, suspension, til kyllinger
Innovax-ILT suspension and solvent for suspension for injection for chickens
Innovax-ILT, suspension og solvens til injektionsvæske, suspension, til kyllinger
Innovax-ILT, suspension and solvent for suspension for injection for chickens
INOmax 400 ppm mol/mol inhalationsgas
INOmax 400 ppm mol/mol inhalation gas
INOmax 800 ppm mol/mol inhalationsgas
INOmax 800 ppm mol/mol inhalation gas
INOmax bør først anvendes, når den konventionelle behandling er optimeret.
INOmax should be used only after conservative support has been optimised.
INOmax bør kun anvendes efter, at resirationsstøtten er optimeret.
INOmax should be used only after respiratory support has been optimised.
INOmax bør kun indgives på ordination af en anæstesiolog eller speciallæge i intensivbehandling.
INOmax should only be delivered according to an anaesthetist’s or intensive care physician’s prescription.
INOmax bør kun indgives på ordination af en neonatal-specialist.
INOmax should only be delivered according to a neonatologist’s prescription.
INOmax kan anvendes hos ventilerede nyfødte spædbørn, der forventes af kræve støtte i >24 timer.
INOmax should be used in ventilated newborn infants expected to require support >24 hours.
INOmax må kun administreres af personale, der er specielt trænet i brug og håndtering af INOmax.
INOmax should be used and administered only by personnel specially trained in the use and handling of INOmax.
INOmax, 400 ppm mol/mol inhalationsgas.
INOmax 400 ppm mol/mol inhalation gas
INOmax, 800 ppm mol/mol inhalationsgas.
INOmax 800 ppm mol/mol inhalation gas
INOmax- behandlingen skal være tilgængelig ved manuel ventilation, så som sug, patient-transport og genoplivning.
INOmax therapy must be available for manual ventilation such as suctioning, patient transport, and resuscitation.
INOmax-flasker skal opbevares sikkert, så de ikke vælter og evt. forvolder skade.
INOmax cylinders should be stored secured in order to avoid falling and thus potentially causing harm.
inoperable eller metastaserende gastrointestinale stromale tumorer (GIST), som progredierede på eller var intolerante overfor tidligere behandling med imatinib og sunitinib.
unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
INOT25- forsøget med undersøgelse af effekterne af iNO til hypoxiske for tidligt fødte børn viste ingen forbedring hos spædbørn, der var i live uden BPD.
The INOT25 trial, studying the effects of iNO in hypoxic preterm neonates, did not show improvement in alive without BPD.
Inovelon 100 mg filmovertrukne tabletter
Inovelon 100 mg film-coated tablets
Inovelon 100 mg filmovertrukne tabletter Inovelon 200 mg filmovertrukne tabletter Inovelon 400 mg filmovertrukne tabletter Rufinamid
Inovelon 100 mg film-coated tablets Inovelon 200 mg film-coated tablets Inovelon 400 mg film-coated tablets Rufinamide
Inovelon 100 mg filmovertrukne tabletter Rufinamid
Inovelon 100 mg film-coated tablets Rufinamide
Inovelon 100 mg tabletter
Inovelon 100 mg tablets
Inovelon 100 mg tabletter er lyserøde, ovale, let hvælvede filmovertrukne tabletter med delekærv på begge sider, præget med ‘Є261’ på den ene side og blanke på den anden side.
Inovelon 100 mg tablets are pink, oval, slightly convex film-coated tablets, scored on both sides, embossed ‘Є261’ on one side and blank on the other side.
Inovelon 200 mg filmovertrukne tabletter
Inovelon 200 mg film-coated tablets
Inovelon 200 mg filmovertrukne tabletter Rufinamid
Inovelon 200 mg film-coated tablets Rufinamide
Inovelon 200 mg tabletter
Inovelon 200 mg tablets
Inovelon 200 mg tabletter er lyserøde, ovale, let hvælvede filmovertrukne tabletter med delekærv på begge sider, præget med ‘Є262’ på den ene side og blanke på den anden side.
Inovelon 200 mg tablets are pink, oval, slightly convex film-coated tablets, scored on both sides, embossed ‘Є262’ on one side and blank on the other side.
Inovelon 400 mg filmovertrukne tabletter
Inovelon 400 mg film-coated tablets
Inovelon 400 mg filmovertrukne tabletter Rufinamid
Inovelon 400 mg film-coated tablets Rufinamide
Inovelon 400 mg tabletter
Inovelon 400 mg tablets
Inovelon 400 mg tabletter er lyserøde, ovale, let hvælvede filmovertrukne tabletter med delekærv på begge sider, præget med ‘Є263’ på den ene side og blanke på den anden side.
Inovelon 400 mg tablets are pink, oval, slightly convex film-coated tablets, scored on both sides, embossed ‘Є263’ on one side and blank on the other side.
Inovelon anvendes til at behandle patienter fra fire år og derover med Lennox-Gastaut syndrom, som er en sjælden form for epilepsi, der normalt rammer børn, men som kan fortsætte ind i voksenalderen.
Inovelon is used to treat patients aged four years or older who have Lennox-Gastaut syndrome, a rare type of epilepsy that usually affects children but which can continue into adulthood.
Inovelon bruges sammen med andre lægemidler til at behandle anfald i forbindelse med Lennox- Gastaut-syndrom hos voksne, unge og børn over 4 år.
Inovelon is used with other medicines to treat seizures associated with Lennox-Gastaut syndrome in adults, adolescents and children over 4 years of age.
Inovelon bruges som et supplement til andre antiepileptika.
Inovelon is used as an add-on to other anti-epileptic medicines.
Inovelon bør ikke anvendes hos patienter med svær leversygdom.
Inovelon should not be used in patients who have severe problems with their liver.
Inovelon bør ikke gives til børn under 4 år, da der ikke er tilstrækkelige oplysninger om brug af lægemidlet til denne aldersgruppe.
Inovelon should not be given to children younger than 4 years of age since there is not enough information on its use in this age group.
Inovelon er en hvid, let viskøs suspension.
Inovelon is a white slightly viscous suspension.
Inovelon er et lægemiddel, der indeholder det aktive stof rufinamid.
Inovelon is a medicine containing the active substance rufinamide.
Inovelon er indiceret til supplerende behandling af anfald (epileptiske), som er associeret med Lennox- Gastaut-syndrom hos patienter på 4 år og ældre.
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older.
Inovelon indeholder lactose og bør derfor ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af hereditær lactasemangel (Lapp Lactase deficiency), eller glucose/galactosemalabsorption.
Inovelon contains lactose, therefore patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Inovelon indeholder lactose.
Inovelon contains lactose
Inovelon indeholder methylparahydroxybenzoat (E218) og propylparahydroxybenzoat (E216):
Inovelon contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)
Inovelon kan reducere virkningen af hormonelle/orale præventionsmidler, såsom p-piller.
Inovelon may make hormonal/oral contraceptives such as the contraceptive pill less effective.
Inovelon kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Inovelon can cause side effects, although not everybody gets them.
Inovelon må ikke anvendes til patienter, der kan være overfølsomme (allergiske) over for rufinamid, triazolderivater (f.eks. visse lægemidler til behandling af svampeinfektioner) eller over for et eller flere af hjælpestofferne.
Inovelon must not be used in patients who are hypersensitive (allergic) to rufinamide, triazole derivatives (such as some medicines used to treat fungal infections) or any of the other ingredients.
Inovelon oral suspension og Inovelon filmovertrukne tabletter har vist sig at være bioækvivalente.
Inovelon oral suspension and Inovelon film coated tablets have been demonstrated to be bioequivalent.
Inovelon oral suspension og Inovelon filmovertrukne tabletter kan udskiftes med hinanden ved lige store doser.
Inovelon oral suspension and Inovelon film coated tablets may be interchanged at equal doses.
Inovelon reducerede antallet og sværhedsgraden af de epileptiske anfald.
Inovelon caused a reduction in the number and severity of seizures.
Inovelon rufinamid
Inovelon rufinamide
Inovelon skal tages sammen med mad.
It should be taken with food.
Inovelon skal tages to gange dagligt, om morgenen og om aftenen.
Inovelon must be taken twice every day, once in the morning and once in the evening.